Amoxicilina + Ácido Clavulânico Ciclum

Amoxicilina + Ácido Clavulânico Ciclum may be available in the countries listed below.

Ingredient matches for Amoxicilina + Ácido Clavulânico Ciclum

Amoxicillin

Amoxicillin is reported as an ingredient of Amoxicilina + Ácido Clavulânico Ciclum in the following countries:

• Portugal

Clavulanate

Clavulanic Acid is reported as an ingredient of Amoxicilina + Ácido Clavulânico Ciclum in the following countries:

• Portugal

International Drug Name Search

Avalide

Avalide is a brand name of hydrochlorothiazide/irbesartan, approved by the FDA in the following formulation(s):

AVALIDE (hydrochlorothiazide; irbesartan - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: September 30, 1997
  
  Strength(s): 12.5MG;150MG ^[RLD]


• 
  Manufacturer: SANOFI AVENTIS
  
  Approval date: August 31, 1998
  
  Strength(s): 12.5MG;300MG
  

Has a generic version of Avalide been approved?

No. There is currently no therapeutically equivalent version of Avalide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avalide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
  Patent 5,270,317
  Issued: December 14, 1993
  Inventor(s): Bernhart; Claude & Breliere; Jean-Claude & Clement; Jacques & Nisato; Dino & Perreault; Pierre & Muneaux; Claude & Muneaux; Yvette
  Assignee(s): Elf Sanofi
  The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula ##STR1## in which the substituents are as defined in the specification. Application: Angiotensin II antagonists
  
  Patent expiration dates:
  
  
  • September 30, 2011
    
  
  
  
  • September 30, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 30, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing irbesartan
  Patent 5,994,348
  Issued: November 30, 1999
  Inventor(s): Ku; Cathy C. & Sprockel; Omar L. & Lang; Beth A. & Desai; Divyakant S.
  Assignee(s): Sanofi
  Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
  
  
  
  • June 7, 2015
    
    ✓ 
    Drug product
  
  
  
  • December 7, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 16, 2010 - USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Avalide Consumer Information (Drugs.com)
• Avalide Consumer Information (Wolters Kluwer)
• Avalide Consumer Information (Cerner Multum)
• Avalide Advanced Consumer Information (Micromedex)
• Irbesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and irbesartan Consumer Information (Cerner Multum)
• Irbesartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Dopadone

Dopadone may be available in the countries listed below.

Ingredient matches for Dopadone

Domperidone

Domperidone is reported as an ingredient of Dopadone in the following countries:

• Bangladesh

International Drug Name Search

Argimate

Argimate may be available in the countries listed below.

Ingredient matches for Argimate

Arginine

Arginine glutamate (a derivative of Arginine) is reported as an ingredient of Argimate in the following countries:

• Japan

International Drug Name Search

Klarmedic

Klarmedic may be available in the countries listed below.

Ingredient matches for Klarmedic

Clarithromycin

Clarithromycin is reported as an ingredient of Klarmedic in the following countries:

• Peru

International Drug Name Search

Tocoferole Acetat

Tocoferole Acetat may be available in the countries listed below.

Ingredient matches for Tocoferole Acetat

Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Tocoferole Acetat in the following countries:

• Georgia

International Drug Name Search

Caniphedrin

Caniphedrin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Caniphedrin

Ephedrine

Ephedrine hydrochloride (a derivative of Ephedrine) is reported as an ingredient of Caniphedrin in the following countries:

• Germany


• Switzerland

International Drug Name Search

Lomper

Lomper may be available in the countries listed below.

Ingredient matches for Lomper

Mebendazole

Mebendazole is reported as an ingredient of Lomper in the following countries:

• Spain

International Drug Name Search

Eyeflur

Eyeflur may be available in the countries listed below.

Ingredient matches for Eyeflur

Flurbiprofen

Flurbiprofen sodium salt (a derivative of Flurbiprofen) is reported as an ingredient of Eyeflur in the following countries:

• Greece

International Drug Name Search

Gonal-f

See also: Generic Gonal-f RFF, Generic Gonal-f RFF Pen

Gonal-f is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):

GONAL-F (follitropin alfa/beta - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: February 28, 2001
  
  Strength(s): 1,050 IU/VIAL
  


• 
  Manufacturer: EMD SERONO
  
  Approval date: March 26, 2004
  
  Strength(s): 450 IU/VIAL ^[RLD]

Has a generic version of Gonal-f been approved?

No. There is currently no therapeutically equivalent version of Gonal-f available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gonal-f. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Follicle stimulating hormone and pharmaceutical compositions containing same
  Patent 5,767,067
  Issued: June 16, 1998
  Inventor(s): Arpaia; Guiseppe & Serani; Serenella & Sirna; Antonino & Villa; Stefano
  Assignee(s): Istituto di Ricerca Cesare Serono S.p.A.
  Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces of LH and other urinary proteins.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  FSH and FSH variant formulations, products and methods
  Patent 7,563,763
  Issued: July 21, 2009
  Inventor(s): Hoffmann; James Arthur & Lu; Jirong
  Assignee(s): Ares Trading S.A.
  This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
  
  Patent expiration dates:
  
  
  • August 23, 2019
    
    ✓ 
    Drug product
  
  

See also...

• Gonal-f Powder Consumer Information (Wolters Kluwer)
• Gonal-F Consumer Information (Cerner Multum)
• Gonal-F Advanced Consumer Information (Micromedex)
• Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
• Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
• Follitropin Beta Consumer Information (Wolters Kluwer)
• Follicle stimulating hormone Consumer Information (Cerner Multum)
• Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)

Retarbolin

Retarbolin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Retarbolin

Nandrolone

Nandrolone 17ß-cyclohexylpropionate (a derivative of Nandrolone) is reported as an ingredient of Retarbolin in the following countries:

• United Kingdom

International Drug Name Search